BioVersys switches off bacterial drug resistance, thus reactivating approved antibiotics.
We develop small chemical molecules, which switch off drug resistance on a gene regulatory level within bacteria, so called TRIC’s (Transcriptional Regulator Inhibitory Compounds). Current pipeline: Gram negative and positive bacteria; Tuberculosis.
BioVersys has signed a major global research collaboration with Shionogi & Co., Ltd. The partnership focuses on the joint development of novel antibiotics for non-tuberculous mycobacteria (NTM), with potential milestone payments of up to CHF 479 million.
BioVersys plans to conduct an initial public offering on the SIX Swiss Exchange in the first quarter of 2025.
BioVersys AG announces first patient dosed in Phase 2a clinical trial with BVL-GSK099, to investigate a new treatment concept to address multidrug-resistance tuberculosis…
| Building | C3 |
|---|---|
| Industry | Biotech |
| Research Topics | Antimicrobial Resistance (AMR) |
| Employees | 18 |
| Founding year | 2010 |
Home 
About us 
Offer 
News 
Financial support for start-ups in Basel 
Media 
Contact 